JP2012506448A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506448A5 JP2012506448A5 JP2011533309A JP2011533309A JP2012506448A5 JP 2012506448 A5 JP2012506448 A5 JP 2012506448A5 JP 2011533309 A JP2011533309 A JP 2011533309A JP 2011533309 A JP2011533309 A JP 2011533309A JP 2012506448 A5 JP2012506448 A5 JP 2012506448A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- combination
- activated prodrug
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000011510 cancer Diseases 0.000 claims description 32
- 239000002246 antineoplastic agent Substances 0.000 claims description 31
- 206010021143 Hypoxia Diseases 0.000 claims description 30
- 230000001146 hypoxic Effects 0.000 claims description 30
- 239000000651 prodrug Substances 0.000 claims description 30
- 229940002612 prodrugs Drugs 0.000 claims description 30
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 10
- 229960005277 gemcitabine Drugs 0.000 claims description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 8
- 229960004679 Doxorubicin Drugs 0.000 claims description 8
- 229960003668 docetaxel Drugs 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 claims description 8
- 229960005079 pemetrexed Drugs 0.000 claims description 8
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 6
- 229960002949 Fluorouracil Drugs 0.000 claims description 6
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 201000005244 lung non-small cell carcinoma Diseases 0.000 claims description 6
- 230000000955 neuroendocrine Effects 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims description 6
- 229960004562 Carboplatin Drugs 0.000 claims description 4
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims description 4
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drugs Drugs 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 230000003442 weekly Effects 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 210000001072 Colon Anatomy 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025650 Malignant melanoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 229960001592 Paclitaxel Drugs 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229950008882 Polysorbate Drugs 0.000 claims description 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 210000003491 Skin Anatomy 0.000 claims description 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical group CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 201000011231 colorectal cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000010893 malignant breast melanoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 201000001219 parotid gland cancer Diseases 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- -1 polyoxyethylene Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 2
- 239000001593 sorbitan monooleate Substances 0.000 claims description 2
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 229930003347 taxol Natural products 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 239000003860 topical agent Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 32
- 210000003462 Veins Anatomy 0.000 claims 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 claims 1
- 239000003560 cancer drug Substances 0.000 claims 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10725308P | 2008-10-21 | 2008-10-21 | |
| US61/107,253 | 2008-10-21 | ||
| US11836808P | 2008-11-26 | 2008-11-26 | |
| US61/118,368 | 2008-11-26 | ||
| US15070009P | 2009-02-06 | 2009-02-06 | |
| US61/150,700 | 2009-02-06 | ||
| US15116309P | 2009-02-09 | 2009-02-09 | |
| US61/151,163 | 2009-02-09 | ||
| US24417209P | 2009-09-21 | 2009-09-21 | |
| US61/244,172 | 2009-09-21 | ||
| PCT/US2009/061541 WO2010048330A1 (en) | 2008-10-21 | 2009-10-21 | Treatment of cancer using hypoxia activated prodrugs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506448A JP2012506448A (ja) | 2012-03-15 |
| JP2012506448A5 true JP2012506448A5 (US20070167479A1-20070719-C00034.png) | 2012-12-13 |
| JP5765634B2 JP5765634B2 (ja) | 2015-08-19 |
Family
ID=42119663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533309A Active JP5765634B2 (ja) | 2008-10-21 | 2009-10-21 | 低酸素活性化型プロドラッグを用いるがんの処置 |
Country Status (5)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1896040B1 (en) | 2005-06-29 | 2012-08-01 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
| RU2597844C2 (ru) | 2010-07-12 | 2016-09-20 | Тресхолд Фармасьютикалз, Инк. | Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака |
| EP2694062A4 (en) | 2011-04-01 | 2014-11-12 | Threshold Pharmaceuticals Inc | METHOD FOR THE TREATMENT OF CANCER |
| AU2012242514A1 (en) * | 2011-04-15 | 2013-10-24 | Threshold Pharmaceuticals, Inc. | Unit dose form for oral administration |
| EP2793882A4 (en) | 2011-12-22 | 2015-04-29 | Threshold Pharmaceuticals Inc | ADMINISTRATION OF HYPOXIA ACTIVATED DRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER |
| WO2013096684A1 (en) * | 2011-12-22 | 2013-06-27 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs and mtor inhibitors for treating cancer |
| US20160045522A1 (en) * | 2012-02-21 | 2016-02-18 | Threshold Pharmaceuticals, Inc. | Treatment of Cancer |
| JP2014001204A (ja) * | 2012-05-23 | 2014-01-09 | Kumamoto Univ | 腫瘍細胞選択的抗がん剤 |
| US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| WO2014069063A1 (ja) | 2012-10-29 | 2014-05-08 | 京セラ株式会社 | 弾性表面波センサ |
| JP2016519107A (ja) * | 2013-04-10 | 2016-06-30 | スレッショルド ファーマシューティカルズ，インコーポレイテッド | Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー |
| JP2016528217A (ja) * | 2013-07-26 | 2016-09-15 | スレッショルド ファーマシューティカルズ，インコーポレイテッド | 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療 |
| US10071109B2 (en) | 2013-11-06 | 2018-09-11 | Molecular Templates, Inc. | Predictive biomarker for hypoxia-activated prodrug therapy |
| CN104628772A (zh) * | 2013-11-07 | 2015-05-20 | 四川恒康发展有限责任公司 | 一种抗肿瘤前药及其激活剂、组合物和应用 |
| EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
| US10131683B2 (en) | 2014-07-17 | 2018-11-20 | Molecular Templates, Inc. | TH-302 solid forms and methods related thereto |
| KR102398323B1 (ko) | 2015-03-10 | 2022-05-16 | 아센타위츠 파마슈티컬즈 리미티드 | Dna 알킬화제 |
| CN112142692A (zh) | 2015-04-02 | 2020-12-29 | 深圳艾欣达伟医药科技有限公司 | 硝基苄基衍生物抗癌试剂 |
| AU2016282785A1 (en) | 2015-06-24 | 2018-02-15 | Immunogenesis, Inc. | Aziridine containing DNA alkylating agents |
| EP3454833B1 (en) * | 2016-05-13 | 2023-05-10 | Teclison Limited | Methods for treating liver tissue |
| JP2019527236A (ja) * | 2016-08-01 | 2019-09-26 | モレキュラー テンプレーツ，インコーポレイティド | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 |
| SI3565806T1 (sl) | 2017-01-06 | 2022-07-29 | Rivus Pharmaceuticals, Inc. | Novi fenilni derivati |
| JP2019094284A (ja) * | 2017-11-21 | 2019-06-20 | 日本化薬株式会社 | ペメトレキセドを含有する注射用溶液製剤 |
| CN109999183B (zh) * | 2019-04-15 | 2021-03-09 | 中国科学技术大学 | 一种含有乏氧激活前药的纳米簇化酶及其制备方法和应用 |
| KR20240051965A (ko) | 2021-08-27 | 2024-04-22 | 아센타위츠 파마슈티컬즈 리미티드 | Th-302를 이용한 parp 억제제에 내성이 있는 환자의 치료 |
| EP4393480A1 (en) * | 2021-08-27 | 2024-07-03 | Ascentawits Pharmaceuticals, Ltd. | Lyophilized formulation solution and lyophilized formulation, and method and use thereof |
| WO2023174319A1 (zh) * | 2022-03-15 | 2023-09-21 | 深圳艾欣达伟医药科技有限公司 | 治疗brca突变癌症患者的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4636195A (en) | 1982-04-02 | 1987-01-13 | Harvey Wolinsky | Method and apparatus for removing arterial constriction |
| EP0383492A3 (en) | 1989-02-14 | 1991-08-07 | Thoro System Products Inc. | Dispersion system for rapid curing cement compositions |
| US5049132A (en) | 1990-01-08 | 1991-09-17 | Cordis Corporation | Balloon catheter for delivering therapeutic agents |
| JPH05507226A (ja) | 1990-06-15 | 1993-10-21 | コートラック・メディカル・インコーポレーテッド | 薬物投与装置および方法 |
| US6017948A (en) | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
| US6060083A (en) | 1999-04-01 | 2000-05-09 | Topical Technologies, Inc. | Topical DMSO treatment for palmar-plantar erythrodysethesia |
| GB9909612D0 (en) | 1999-04-26 | 1999-06-23 | Cancer Res Campaign Tech | N-protected amines and their use as prodrugs |
| EP1191923A4 (en) | 1999-06-11 | 2004-05-06 | Henceforth Hibernia Inc | ANTIOXIDANT COMPOSITIONS FOR PROPHYLACTIC, THERAPEUTIC AND INDUSTRIAL USE IMPROVED BY STABILIZED ATOMIC HYDROGEN, AND / OR FREE ELECTRONS AND METHODS OF PREPARING AND USING SAME |
| JP2005508838A (ja) * | 2001-03-23 | 2005-04-07 | アフトン コーポレーション | 膵癌の組合せ治療 |
| NZ521851A (en) | 2002-10-08 | 2005-02-25 | Auckland Uniservices Ltd | Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| US7629332B2 (en) | 2003-10-31 | 2009-12-08 | Auckland Uniservices Limited | Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents |
| WO2005086951A2 (en) | 2004-03-10 | 2005-09-22 | Threshold Pharmaceuticals, Inc. | Hypoxia-activated anti-cancer agents |
| SE0400642D0 (sv) | 2004-03-15 | 2004-03-15 | Electrolux Ab | Floor cleaning implement |
| KR20070086595A (ko) | 2004-11-22 | 2007-08-27 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 튜불린 결합 항암제 및 이의 전구약물 |
| US20070117784A1 (en) | 2005-03-04 | 2007-05-24 | Novacea, Inc. | Treatment of hyperproliferative diseases with anthraquinones |
| WO2006113479A2 (en) | 2005-04-15 | 2006-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy |
| EP1896040B1 (en) * | 2005-06-29 | 2012-08-01 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
| WO2007041546A2 (en) | 2005-10-03 | 2007-04-12 | Genetix Pharmaceuticals, Inc. | Method for selectively depleting hypoxic cells |
| CN101421282B (zh) | 2006-02-17 | 2013-08-14 | 俄勒冈州由俄勒冈州立大学代表高等教育委员会行使 | 用长春花生物碱n-氧化物和类似物治疗过度增殖性疾病 |
| EP2114157B1 (en) | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Phosphoramidate alkylator prodrug for the treatment of cancer |
| WO2008151253A1 (en) | 2007-06-04 | 2008-12-11 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of antineoplastic agents |
| WO2009018163A1 (en) | 2007-07-27 | 2009-02-05 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of anthracyclines |
| WO2009033165A1 (en) | 2007-09-06 | 2009-03-12 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of bis-alkylating agents |
-
2009
- 2009-10-21 WO PCT/US2009/061541 patent/WO2010048330A1/en active Application Filing
- 2009-10-21 ES ES09822657T patent/ES2884674T3/es active Active
- 2009-10-21 US US13/125,303 patent/US8946275B2/en active Active
- 2009-10-21 EP EP09822657.4A patent/EP2350664B1/en active Active
- 2009-10-21 JP JP2011533309A patent/JP5765634B2/ja active Active
-
2014
- 2014-12-17 US US14/574,082 patent/US20150258125A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012506448A5 (US20070167479A1-20070719-C00034.png) | ||
| JP5765634B2 (ja) | 低酸素活性化型プロドラッグを用いるがんの処置 | |
| Matsumura | Poly (amino acid) micelle nanocarriers in preclinical and clinical studies | |
| Matsumura | Polymeric micellar delivery systems in oncology | |
| JP4788774B2 (ja) | 抗癌剤の併用による癌治療方法 | |
| JP2010514787A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2013503174A5 (US20070167479A1-20070719-C00034.png) | ||
| Homesley et al. | A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients | |
| Kaira et al. | A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer | |
| JP2013527233A5 (US20070167479A1-20070719-C00034.png) | ||
| Petrelli et al. | 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials | |
| JP2011511072A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2011079858A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2013527232A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2012509889A5 (US20070167479A1-20070719-C00034.png) | ||
| Ueda et al. | Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer | |
| JP2019521180A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| JP2020523356A5 (US20070167479A1-20070719-C00034.png) | ||
| Kim et al. | A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer | |
| Syrigou et al. | Acute hypersensitivity reactions to chemotherapy agents: an overview | |
| JP2012522837A5 (US20070167479A1-20070719-C00034.png) | ||
| Nabell et al. | Docetaxel with concurrent radiotherapy in head and neck cancer | |
| Kobayashi et al. | Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan | |
| Sendo et al. | Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy |
